Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

551 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Corrigendum to "Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial" [Eur J Cancer 198 (2024) 113475].
Le Rhun E, Gorlia T, Felsberg J, Jongen J, Maurage CA, Ducray F, Gramatzki D, Hau P, Chinot OL, Preusser M, Cartalat S, Roth P, van den Bent M, Furtner J, Collienne M, Reifenberger G, Weller M. Le Rhun E, et al. Among authors: van den bent m. Eur J Cancer. 2024 Jun;204:114066. doi: 10.1016/j.ejca.2024.114066. Epub 2024 Apr 23. Eur J Cancer. 2024. PMID: 38658199 Free article. No abstract available.
Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study.
Lamers LM, Stupp R, van den Bent MJ, Al MJ, Gorlia T, Wasserfallen JB, Mittmann N, Jin Seung S, Crott R, Uyl-de Groot CA; EORTC 26981/22981 NCI-C CE3 Intergroup Study. Lamers LM, et al. Among authors: van den bent mj. Cancer. 2008 Mar 15;112(6):1337-44. doi: 10.1002/cncr.23297. Cancer. 2008. PMID: 18213621 Free article. Clinical Trial.
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.
Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W, Osoba D, Rossiter JP, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Golfinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert BG, Wick W, Ding K, Mason WP; Trial Investigators. Perry JR, et al. N Engl J Med. 2017 Mar 16;376(11):1027-1037. doi: 10.1056/NEJMoa1611977. N Engl J Med. 2017. PMID: 28296618 Free article. Clinical Trial.
Retraction Note: Neurocognitive impairment and patient-proxy agreement on health-related quality of life evaluations in recurrent high-grade glioma patients.
Caramanna I, Klein M, van den Bent M, Idbaih A, Wick W, Taphoorn MJB, Dirven L, Bottomley A, Reijneveld JC; EORTC Quality of Life Group and EORTC Brain Tumor Group. Caramanna I, et al. Among authors: van den bent m. Qual Life Res. 2024 Aug;33(8):2297. doi: 10.1007/s11136-024-03696-y. Qual Life Res. 2024. PMID: 38819763 Free PMC article. No abstract available.
Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data.
Martinelli F, Quinten C, Maringwa JT, Coens C, Vercauteren J, Cleeland CS, Flechtner H, Gotay C, Greimel E, King M, Mendoza T, Osoba D, Reeve BB, Ringash J, Koch JS, Shi Q, Taphoorn MJ, Weis J, Bottomley A; European Organisation for Research and Treatment of Cancer Clinical Groups. Martinelli F, et al. Expert Rev Pharmacoecon Outcomes Res. 2011 Oct;11(5):587-99. doi: 10.1586/erp.11.51. Expert Rev Pharmacoecon Outcomes Res. 2011. PMID: 21958103
Reply.
Ellingson BM, Sanvito F, Pope WB, Cloughesy TF, Huang RY, Villanueva-Meyer JE, Barboriak DP, Shankar LK, Smits M, Kaufmann TJ, Boxerman JL, Weller M, Galanis E, Groot J, Chang SM, Gilbert MR, Lassman AB, Shiroishi MS, Nabavizadeh A, Mehta M, Stupp R, Wick W, Reardon DA, Wen PY, Vogelbaum MA, van den Bent M. Ellingson BM, et al. Among authors: van den bent m. AJNR Am J Neuroradiol. 2025 Jan 8;46(1):221-222. doi: 10.3174/ajnr.A8621. AJNR Am J Neuroradiol. 2025. PMID: 39730160 No abstract available.
The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.
de la Fuente MI, Touat M, van den Bent MJ, Preusser M, Peters KB, Young RJ, Huang RY, Ellingson BM, Capper D, Phillips JJ, Halasz LM, Shih HA, Rudà R, Lim-Fat MJ, Blumenthal DT, Weller M, Arakawa Y, Whittle JR, Ducray F, Reardon DA, Bi WL, Minniti G, Rahman R, Hervey-Jumper S, Chang SM, Wen PY. de la Fuente MI, et al. Among authors: van den bent mj. Neuro Oncol. 2024 Dec 25:noae259. doi: 10.1093/neuonc/noae259. Online ahead of print. Neuro Oncol. 2024. PMID: 39723472
Practical and statistical aspects of subgroup analyses in surgical neuro-oncology: A comprehensive review from the PIONEER Consortium.
Gerritsen JKW, Karschnia P, Young JS, van den Bent MJ, Chang SM, Smith TR, Nahed BV, Rincon-Torroella J, Bettegowda C, Sanai N, Krieg SM, Maruyama T, Schucht P, Broekman MLD, Tonn JC, Wen PY, De Vleeschouwer S, Vincent AJPE, Hervey-Jumper S, Berger MS, Mekary RA, Molinaro AM. Gerritsen JKW, et al. Among authors: van den bent mj. Neuro Oncol. 2024 Dec 7:noae261. doi: 10.1093/neuonc/noae261. Online ahead of print. Neuro Oncol. 2024. PMID: 39657588
551 results